

Ref: EPL/CS/SE/0022/2025

Date: April 04, 2025

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Script Symbol: EMCURE	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001 Scrip Code/Symbol: 544210/ EMCURE
--	---

Dear Sir/Madam,

Subject: Press Release

Please find enclosed herewith a Press Release titled "Emcure's European subsidiary Tillomed acquires strategic pharma portfolio from Manx".

You are requested to take the same on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Chetan Sharma
Company Secretary & Compliance Officer
Membership Number: F8352

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

Emcure's European subsidiary Tillomed acquires strategic pharma portfolio from Manx

Pune, India & London, UK, April 04, 2025: Tillomed Laboratories Limited, a subsidiary of Emcure Pharmaceuticals Ltd. (BSE: 544210, NSE: EMCURE) and a leading European pharma company, has entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare Limited and its subsidiaries Manx Pharma Ltd and Manx Generics Limited (collectively Manx).

Under the APA, Tillomed will acquire Manx's product portfolio inclusive of relevant Dossiers, Marketing Authorisations, Intellectual Property (collectively Intellectual Properties) and the relevant stocks for around £ 19.7 mn (including £ 4.7mn for inventory) of which £ 6.2 mn will be upfront and rest as milestone payments over the next 18 months. The deal marks a strategic milestone for Tillomed and will strengthen the company's product offerings, expand its market reach, and enhance its ability to meet the evolving needs of patients.

Commenting on the development, Ajit Srimal, CEO Tillomed said, "Through the acquisition of Manx's established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions. The acquired assets will help diversify our portfolio and strengthen our market presence."

About Tillomed

Tillomed Laboratories Limited, a subsidiary of Emcure Pharmaceuticals Ltd., is a leading European pharmaceutical company focused on developing, licensing, and marketing high-quality generic medicines. Headquartered in Luton, UK, Tillomed operates across multiple European markets, ensuring access to cost-effective healthcare solutions. As an Emcure subsidiary, Tillomed leverages world-class research, manufacturing, and distribution expertise to bring innovative and affordable medicines to patients. With a portfolio of over 100 products, Tillomed is committed to ensure access to quality healthcare solutions across Europe.

About Emcure

Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune, India engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 12th largest pharma company in India in terms of Domestic Sales for MAT June 2024. Emcure is present in 70+ countries globally including Europe and Canada.

Media Contact:

Naveen.soni@Emcure.com